Michael Morris discusses integrating PSMA PET into high-risk biochemical recurrence, where systemic therapy follows the EMBARK regimen. Dr. Morris treats PSMA-avid oligoprogressive lesions with ...
(UroToday.com) The 2026 ProsTIC annual meeting featured a Lutetium-177 session and a presentation by Dr. Arun Azad discussing appropriate use of 177 Lu-PSMA-617 in 2026. Rather than focusing solely on ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
The Prostate Cancer Foundation framework summarizes five major components used for risk stratification: PSA level, tumor grade on biopsy, T stage, extent of disease including nodal or distant ...
(UroToday.com) The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Sidney Levy discussing the choice of the right PSMA radiotracer. Dr. Levy began by reviewing ...
Dr. Eiber then outlined why standardized reporting is particularly important for PSMA PET. From a clinical perspective, standardization allows nuclear medicine physicians, radiologists, urologists, ...
To compare treatment trends and survival between bladder‑preserving (BP) therapy and radical cystectomy (RC) in patients with T2N0M0 muscle‑invasive bladder cancer (MIBC) using a large ...
(UroToday.com) The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Daniel Moon discussing the PRIMARY 2 study. mpMRI has become an important component of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results